Published in Lancet on June 21, 2008
A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod | NCT00349193
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol (2011) 2.55
Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol (2009) 2.43
Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov (2012) 2.29
Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol (2009) 1.65
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol (2012) 1.53
Multiple sclerosis-a quiet revolution. Nat Rev Neurol (2015) 1.47
Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One (2012) 1.39
Current concepts of hyperinflammation in chronic granulomatous disease. Clin Dev Immunol (2011) 1.36
Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord (2012) 1.31
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol (2014) 1.18
The impact of utilizing different optical coherence tomography devices for clinical purposes and in multiple sclerosis trials. PLoS One (2011) 1.09
MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat Rev Neurol (2011) 1.03
Therapeutic strategies in childhood multiple sclerosis. Ther Adv Neurol Disord (2010) 1.01
Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters. Mult Scler (2010) 1.00
Treatment of multiple sclerosis: current concepts and future perspectives. J Neurol (2011) 0.98
Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits. Drug Healthc Patient Saf (2013) 0.97
Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents. Patient Prefer Adherence (2011) 0.96
New approaches in the management of multiple sclerosis. Drug Des Devel Ther (2010) 0.92
Multiple sclerosis treatment and infectious issues: update 2013. Clin Exp Immunol (2014) 0.90
Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis. Brain Behav (2013) 0.90
Two-year serial whole-brain N-acetyl-L-aspartate in patients with relapsing-remitting multiple sclerosis. Neurology (2012) 0.88
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach. Drug Des Devel Ther (2012) 0.85
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol (2012) 0.84
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. Ther Clin Risk Manag (2010) 0.83
Multiple sclerosis: overview of disease-modifying agents. Perspect Medicin Chem (2014) 0.82
Regression to the mean and predictors of MRI disease activity in RRMS placebo cohorts--is there a place for baseline-to-treatment studies in MS? PLoS One (2015) 0.82
Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study. Immun Inflamm Dis (2015) 0.82
Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Exp Neurol (2014) 0.81
Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Des Devel Ther (2011) 0.81
The evolving role of the multiple sclerosis nurse: an international perspective. Int J MS Care (2011) 0.81
Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod. Ther Clin Risk Manag (2013) 0.81
Remyelination Therapy in Multiple Sclerosis. Front Neurol (2015) 0.79
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat (2013) 0.79
Recent developments in multiple sclerosis therapeutics. BMC Med (2009) 0.79
Promising treatments of tomorrow for multiple sclerosis. Ann Indian Acad Neurol (2009) 0.79
Oral disease-modifying therapies for multiple sclerosis. J Clin Neurol (2015) 0.78
Emerging therapies for treatment of multiple sclerosis. J Inflamm Res (2010) 0.78
Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets. Ther Clin Risk Manag (2010) 0.78
Efficacy and safety of laquinimod in multiple sclerosis: current status. Ther Adv Neurol Disord (2013) 0.77
New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come. J Cent Nerv Syst Dis (2012) 0.77
Laquinimod therapy in multiple sclerosis: a comprehensive review. Neurol Ther (2014) 0.77
The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications. J Neural Transm (Vienna) (2012) 0.76
Y27, a novel derivative of 4-hydroxyquinoline-3-formamide, prevents the development of murine systemic lupus erythematosus-like diseases in MRL/lpr autoimmune mice and BDF1 hybrid mice. Arthritis Res Ther (2012) 0.76
Defining a role for laquinimod in multiple sclerosis. Ther Adv Neurol Disord (2014) 0.75
Recent advances in the treatment of multiple sclerosis. J Exp Pharmacol (2010) 0.75
Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials. Int J MS Care (2017) 0.75
Laquinimod in the treatment of multiple sclerosis: a review of the data so far. Drug Des Devel Ther (2016) 0.75
New oral disease-modifying therapies for multiple sclerosis. F1000 Med Rep (2009) 0.75
The Latest Innovations in the Drug Pipeline for Multiple Sclerosis. Am Health Drug Benefits (2015) 0.75
Update on immunopathogenesis and immunotherapy in multiple sclerosis. Immunotargets Ther (2013) 0.75
Laquinimod, a new oral drug for multiple sclerosis. Lancet (2008) 0.75
Benefits versus risks of latest therapies in multiple sclerosis: a perspective review. Ther Adv Drug Saf (2012) 0.75
Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr (1984) 9.61
Development of a short 'readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict (1992) 5.02
Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med (1970) 4.90
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55
Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis (1978) 4.00
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2003) 3.21
Central nervous system sarcoidosis--diagnosis and management. QJM (1999) 3.11
White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry (2002) 2.72
Cutaneous reactions and antibody response to meningococcal group C polysaccharide vaccines in man. J Infect Dis (1970) 2.71
Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Organ (1971) 2.64
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology (2012) 2.60
The pathology of the joint tissues and its clinical relevance in prosthesis failure. Clin Orthop Relat Res (1976) 2.46
Disseminated fusarial infection in the immunocompromised host. Rev Infect Dis (1989) 2.46
Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr (1990) 2.28
Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain (2000) 2.28
2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy. Lancet (1997) 2.28
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology (2011) 2.26
Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: effect of injection site and needle length. Pediatrics (1989) 2.21
Acetaminophen prophylaxis of adverse reactions following vaccination of infants with diphtheria-pertussis-tetanus toxoids-polio vaccine. Pediatr Infect Dis J (1987) 2.20
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Identification of an epidemic strain of group C Neisseria meningitidis by bactericidal serotyping. J Infect Dis (1971) 2.17
Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest (1975) 2.16
Results from the 1995 National College Health Risk Behavior Survey. J Am Coll Health (1997) 2.13
Pattern of brain tissue loss associated with freezing of gait in Parkinson disease. Neurology (2012) 2.13
Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease. N Engl J Med (1991) 2.05
Default-mode network dysfunction and cognitive impairment in progressive MS. Neurology (2010) 2.03
[Fumaric acid as therapeutic agent for multiple sclerosis]. Nervenarzt (2014) 1.97
Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology (2003) 1.94
Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain (2001) 1.91
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. AJNR Am J Neuroradiol (2000) 1.88
Etiology of acute childhood encephalitis at The Hospital for Sick Children, Toronto, 1994-1995. Clin Infect Dis (1998) 1.85
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology (1999) 1.82
Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler (2005) 1.81
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80
Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology (2004) 1.77
Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology (2001) 1.76
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology (2008) 1.76
Correlation of multiple sclerosis measures derived from T2-weighted, T1-weighted, magnetization transfer, and diffusion tensor MR imaging. AJNR Am J Neuroradiol (2001) 1.75
The contribution of voxel-based morphometry in staging patients with mild cognitive impairment. Neurology (2006) 1.72
Survey of parents' attitudes to the recommended Haemophilus influenzae type b vaccine program. CMAJ (1987) 1.72
Asebia-2J (Scd1(ab2J)): a new allele and a model for scarring alopecia. Am J Pathol (2000) 1.71
Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler (2006) 1.70
Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. Mult Scler (2008) 1.70
Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch Neurol (2005) 1.69
A method for obtaining tract-specific diffusion tensor MRI measurements in the presence of disease: application to patients with clinically isolated syndromes suggestive of multiple sclerosis. Neuroimage (2005) 1.68
Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis (1979) 1.67
Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol (2000) 1.66
Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis. Lancet (1975) 1.66
Subdural haematoma: a potentially serious consequence of spontaneous intracranial hypotension. J Neurol Neurosurg Psychiatry (2003) 1.64
A diffusion tensor MRI study of cervical cord damage in benign and secondary progressive multiple sclerosis patients. J Neurol Neurosurg Psychiatry (2009) 1.64
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol (2008) 1.63
Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology (2008) 1.63
Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol (2006) 1.62
Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. Neurology (2007) 1.62
Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia. J Antimicrob Chemother (1983) 1.60
Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain (2003) 1.60
Cellular immune response to acetylcholine receptor-rich fraction, in patients with myasthenia gravis. Clin Exp Immunol (1975) 1.59
Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology (2010) 1.58
Voxelwise assessment of the regional distribution of damage in the brains of patients with multiple sclerosis and fatigue. AJNR Am J Neuroradiol (2011) 1.58
In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J Clin Invest (1988) 1.57
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology (2007) 1.56
Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? Brain (1999) 1.56
Comparison of three MR sequences for the detection of cervical cord lesions in patients with multiple sclerosis. AJNR Am J Neuroradiol (1999) 1.54
Magnetic resonance imaging, magnetisation transfer imaging, and diffusion weighted imaging correlates of optic nerve, brain, and cervical cord damage in Leber's hereditary optic neuropathy. J Neurol Neurosurg Psychiatry (2001) 1.51
Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics (1977) 1.50
Early anticoagulation in patients with prosthetic heart valves and intracerebral hematoma. Neurology (1998) 1.50
Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am J Pathol (1993) 1.50
Diffusion MRI in multiple sclerosis. Neurology (2005) 1.49
Superficial siderosis of the central nervous system: pathogenetic heterogeneity and therapeutic approaches. Acta Neurol Scand (2003) 1.49
In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain (2007) 1.48
Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol (1993) 1.48
Global N-acetylaspartate declines even in benign multiple sclerosis. AJNR Am J Neuroradiol (2010) 1.47
Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46
Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene. Ann Neurol (1998) 1.46
["Chronic cerebrospinal venous insufficiency" and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients]. Nervenarzt (2010) 1.45
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology (2007) 1.45
Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis. J Neurol Neurosurg Psychiatry (2000) 1.43
High frequency of hemorrhagic strokes in Jerusalem during the Persian Gulf War. Neurology (1992) 1.43
Experimental autoimmune myasthenia induced in monkeys by purified acetylcholine receptor. Nature (1975) 1.43
Abnormal cervical cord function contributes to fatigue in multiple sclerosis. Mult Scler (2012) 1.42
The "mirror-neuron system" in MS: A 3 tesla fMRI study. Neurology (2007) 1.42
Impaired ambulation and steroid therapy impact negatively on bone health in multiple sclerosis. Eur J Neurol (2014) 1.42
An association between multiple sclerosis and type I diabetes mellitus. J Neurol (1992) 1.42
A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. A clinicopathologic analysis of 51 cases. Clin Orthop Relat Res (1985) 1.42